Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.2.3.23 (
GAS
)
957
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Class II transactivator
(
CIITA
) is required for both constitutive and inducible expression of MHC class II genes. IFN-gamma induced expression of
CIITA
in various cell types is directed by
CIITA
type IV promoter. The two transactivators, STAT1 and IRF-1, mediate the IFN-gamma activation of the type IV promoter by binding to the
GAS
and IRF-E of the promoter, respectively. In addition to IRF-1, IRF-2, another member of the IRF family, also activates the human
CIITA
type IV promoter, and IRF-2 cooperates with IRF-1 to activate the promoter in transient transfection assays. IRF-1 and IRF-2 can co-occupy the IRF-E of the human
CIITA
type IV promoter. To understand the effect of loss of IRF-2 on the endogenous
CIITA
expression, we assayed for
CIITA
expression in IRF-2 knock-out mice. Both basal and IFN-gamma induced
CIITA
expression were reduced in IRF-2 knock-out mice. At least half of the amount of inducible
CIITA
mRNA depends on IRF-2. The reduction of IFN-gamma induced
CIITA
mRNA in IRF-2 knock-out mice was due to the reduction of the type IV
CIITA
mRNA induction. The reduction of basal
CIITA
mRNA was apparently due to the reduction of
CIITA
mRNA originating from other promoters. These data indicate that IRF-2, like IRF-1, plays a critical role in the regulation of the endogenous
CIITA
gene. The implications in understanding the previously described phenotypes of IRF-2 defective mice are discussed.
...
PMID:Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. 1146 88